Treating Hearing Loss May Slow Cognitive Decline in Older Adults
A landmark RCT tests whether hearing aids can protect brain health in 977 older adults over 3 years.
Summary
The ACHIEVE study is a completed randomized controlled trial that tested whether treating age-related hearing loss could slow cognitive decline in older adults. Nearly 977 participants aged 70 to 84 with hearing loss but normal cognition were enrolled and randomly assigned to either receive a full hearing intervention — including hearing devices, counseling, and education — or a healthy aging education program as a control. Participants were followed for three years. This trial is highly significant because hearing loss is one of the most prevalent and modifiable risk factors for dementia, yet rarely targeted in clinical prevention strategies. Results from this study could reshape how clinicians approach hearing care as a tool for brain health preservation in aging populations.
Detailed Summary
Dementia prevention remains one of the most urgent challenges in aging medicine. Among the many modifiable risk factors identified, hearing loss stands out as both highly prevalent in older adults and potentially addressable through intervention. The ACHIEVE study was designed to rigorously test whether correcting hearing loss could translate into measurable protection against cognitive decline.
The trial enrolled 977 cognitively normal adults aged 70 to 84 who had documented hearing loss. Nested within the established Atherosclerosis Risk in Communities cohort, participants were randomized 1:1 to either a comprehensive hearing intervention — encompassing hearing needs assessment, fitting of hearing aids, and education and counseling — or a successful aging health education program serving as an active control. This active comparator design is methodologically important, as it controls for the social engagement and attention effects of study participation.
Participants were followed semi-annually for three years, with cognitive assessments tracking changes over time. The study was sponsored by Johns Hopkins Bloomberg School of Public Health and completed in June 2023, meaning full results are available or forthcoming. With nearly 1,000 participants and a rigorous design, ACHIEVE is among the most definitive trials yet conducted on this question.
The implications are substantial. If hearing intervention meaningfully slows cognitive decline, it would represent a scalable, low-risk, and widely accessible dementia prevention strategy. Given that roughly two-thirds of adults over 70 have some degree of hearing loss, and hearing aid adoption remains low globally, this could inform both clinical guidelines and public health policy.
Caveats include that this summary is based on the abstract alone, as the full publication was not available. Results data were not included in the source material reviewed. Additionally, the 3-year follow-up may be insufficient to capture longer-term cognitive trajectories.
Key Findings
- 977 older adults with hearing loss randomized to hearing aids or health education control over 3 years.
- Trial tests whether hearing intervention can directly slow cognitive decline, not just improve hearing.
- Active control group rules out social engagement as confounding explanation for any cognitive benefit.
- Nested in the ARIC cohort, providing rich longitudinal health data to contextualize results.
- Completed June 2023 — full results are available or imminently forthcoming from this landmark trial.
Methodology
ACHIEVE is a phase NA randomized controlled trial nested within the ARIC cohort, enrolling 977 cognitively normal adults aged 70–84 with hearing loss, randomized 1:1 to hearing intervention or active health education control. Participants were followed semi-annually for 3 years with cognitive assessments. The active comparator design strengthens causal inference by controlling for non-specific effects of study engagement.
Study Limitations
This summary is based on the abstract only, as the full publication was not available; key outcomes data and statistical results are not included here. The 3-year follow-up window may be insufficient to capture the full magnitude of hearing intervention effects on dementia risk. Generalizability may be limited by the study's reliance on the existing ARIC cohort population.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.